EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection

Part of paid clinical trials in La Jolla, California.

Sponsor
University of California, San Diego
Study ID
NCT02689518
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

  • Intravitreal aflibercept injection — DRUG
    Intravitreal aflibercept injection 2 mg (0.05 mL) administered every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) intravitreal injection once every 8 weeks(2 months) with the option to treat monthly based on retreatment criteria for a total duration of 12 months.

Study Details

Clinical and genetic evaluation of individuals treated with intravitreal aflibercept injection (Eylea) for neovascular age-related macular degeneration (wet AMD)

Key Dates

Start date
Apr 30, 2014
Status verified
Mar 2021
Primary completion
Nov 12, 2019
Completion
Nov 12, 2019

Study Design

Enrollment
50 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: Treatment - On-Label
    On-label intravitreal aflibercept (Eylea) injection 2 mg (0.05 mL) administered every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) intravitreal injection once every 8 weeks (2 months) with the option to treat monthly based on retreatment criteria for a total duration of 12 months

Primary Outcome Measure

Anatomic Response [ Time Frame: 12 Months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Shiley Eye CenterLa JollaCalifornia92126-

Find similar trials in La Jolla, CA

By condition
Age-related macular degeneration
By specialty
OphthalmologyRetina
By research site
Shiley Eye Center· La Jolla, CA

Related Studies